Table 1. Characteristics of patients and studies included in the meta-analysis comparing EUS-FNA with and without ROSE.
| Reference | year | Country | center | design | No. | needle size, G | age, years (mean±SD) | male sex(%) | lesion size (mm) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROSE+ | ROSE- | ROSE+ | ROSE- | ROSE+ | ROSE- | |||||||
| Alsohaibani | 2009 | Canada | single | R | 102 | 22 | 61,range(26–86) | 65,range(23–84) | 27(49) | 23(49) | NR | NR |
| eveland | 2010 | USA | single | R | 247 | 22 | NR | NR | NR | NR | NR | NR |
| Iglesias-Garcia, | 2011 | Spain | single | R | 182 | 22 | 62 range(24–84) | 59 range(20–83) | 57(60) | 52(60) | 31.7±13.6 | 30.7±12.9 |
| Cermak | 2012 | USA | single | R | 381 | 22 | NR | NR | NR | NR | NR | NR |
| Nayar | 2013 | UK | single | R | 179 | 22/25 | 63.1±17 | 64.4±15 | 48(48.5) | 41(50) | 32.6±23 | 34.7±19 |
| Ganc | 2015 | Brazil | single | R | 48 | 22 | NR | NR | NR | NR | NR | NR |
| Wani | 2015 | USA | multicenter | RCT | 241 | 22 | 66.1(10.2) | 65.6(11.7) | 74(61.2) | 75(62.5) | 3.3(1.4) | 3.2(1.2) |
R, retrospective; RCT, randomized controlled trial; NR, not reported.